Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
Date:2/12/2013

WASHINGTON, Feb. 12, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2012.

Key Highlights:

  • Vanda reported positive SET and RESET Phase III efficacy studies for tasimelteon in the treatment of patients with Non-24-Hour Disorder (Non-24).  Study results demonstrate tasimelteon is a unique circadian regulator that resets the master body clock and improves clinical symptoms in patients with Non-24.
  • The tasimelteon Non-24 program continues towards the goal of a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA). 
  • All tasimelteon activities have been discontinued related to the Major Depressive Disorder (MDD) indication.  In January 2013, Vanda announced that the MAGELLAN Phase IIb/III clinical study did not meet its primary endpoint.
  • Vanda has formally requested a re-examination of the negative opinion issued by the European Medicines Agency (EMA) recommending against approval of Fanaptum™ (oral iloperidone tablets) in the European Union. 
  • Vanda recorded full year 2012 revenue of $32.7 million including Fanapt® royalties of $5.9 million.  Fanapt® prescriptions, as reported by IMS, were approximately 38,200 for the fourth quarter of 2012.  This represents a 1% decrease versus third quarter 2012 prescriptions and a 13% increase over fourth quarter 2011 prescriptions.

  • FULL YEAR 2012 REPORTED RESULTSTotal revenues for the full year 2012 were $32.7 million, compared to $31.3 million for 2011. 
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
    2. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
    3. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
    4. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
    5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
    6. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
    7. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
    8. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
    9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
    10. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
    11. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
    (Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
    (Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
    Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
    ... SANTA BARBARA, Calif., Dec. 6, 2010 Direct ... has donated critically needed medical supplies to assist cholera ... University Hospital (JUH) in Cap-Haitien. JUH is the main public ... I.V. solutions and supplies will also be distributed to the ...
    ... DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, ... of their first-in-class CK2 inhibitor at the 52nd Annual Meeting ... on December 4-7 in Orlando, FL, the company announced today. ... on targeting CK2, a protein kinase that is essential for ...
    Cached Medicine Technology:CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3
    (Date:8/1/2014)... -- Patients with the progressive, deadly respiratory ailment known ... weapon to battle the disease, the U.S. Food and ... a new treatment, an inhaled spray called Striverdi Respimat ... COPD, which is often linked to smoking, involves multiple ... Patients with COPD may experience a number of ...
    (Date:8/1/2014)... -- Although many parents worry about their children choking on ... food. Such was the case for 15-month-old Landon ... handful of nuts. "At the time, Landon had a ... related to his illness or choking," recalled his mother, Ula ... become lodged in his windpipe and had to be removed ...
    (Date:8/1/2014)... 2014 The North America Endpoint Security ... market in North America with analysis and forecast of ... $3.53 billion in 2014 to $4.77 billion by 2019, ... , Browse through the TOC of the North America ... the in-depth analysis provided. It also provides a glimpse ...
    (Date:8/1/2014)... York, NY (PRWEB) August 01, 2014 ... Dentists industry have benefited from innovative technologies that ... that resemble a patient's tooth color. Moreover, the ... dentistry due to age-related tooth ailments. Due to ... decay, many elderly individuals have demanded dental fillings, ...
    (Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... in digestion help keep the intestinal lining intact. The ... could yield new therapies for inflammatory bowel disease (IBD) ... research involved the intestinal microbiome, which contains some 100 ... or preventing disease is a major emerging field of ...
    Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
    ... March 21 SRI International, an independent nonprofit research and development organization, will present preliminary results of a diagnostic to detect neglected tropical ... Francisco . , ... , , ... ...
    ... , March 21 "Tonight,s historic vote marks ... of the insurance industry and provide quality, affordable health care ... the determined leadership of President Barack Obama and ... necessary to defeat the special interests and do what is ...
    ... African American and white cancer patients are treated at ... equal. Published early online in Cancer , a ... suggest that where patients receive care may partly explain ... new study, researchers led by Tracy Onega, PhD, MA, ...
    ... A look ... you by the health coverage experts at the Center for Children and Families at Georgetown ... (PRWEB) March 22, ... Following Statement on Health Reform Passed by U.S. House of Representatives Today:, , ,The House ...
    ... , president and founder of the conservative grassroots public policy organization Eagle Forum, made the following remarks after the public announcement that formerly pro-life Democrat Bart Stupak ... ... , ... ...
    ... the House is expected to approve today, according to Congressman Chaka Fattah (D-PA-02). , ... , , ... ... "Small businesses ...
    Cached Medicine News:Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 2Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 3Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 4Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 5Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 6Health News:'A Monumentally Important Victory for Our Country' 2Health News:Racial disparities diminish in specialized cancer centers 2Health News:Georgetown University Center for Children and Families Hails Health Reform As Big Win for Children and Families 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 3Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 2Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 3
    Lab-Reader...
    Fully automatic NRTL and CE certified microplate reader....
    The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
    EL301 Microwell Strip Reader is a portable, rugged, single/dual wavelength photometer designed to measure and interpret the absorbances of microwell strip assays....
    Medicine Products: